Mobile

A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndr...

Update Il y a 4 ans
Reference: EUCTR2007-005103-18

A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS)

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in stable CHD patients, with a documented recent ACS.

Inclusion criteria

  • Stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS)

Links